S. Pharmacol Res 2008, 57:283?89. 103. Collier BR, Giladi A, Dossett LA, Dyer L, Fleming SB, Cotton BA: Impact of high-dose antioxidants on MK-1439 web outcomes in acutely injured patients. JPEN J Parenter Enteral Nutr 2008, 32:384?88. 104. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 2002, 236:814?22. 105. Berger MM, Soguel L, Shenkin A, Revelly JP, Pinget C, Baines M, Chiolero RL: Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. Crit Care 2008, 12:R101. 106. Heyland D, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28461585 Muscedere J, Wischmeyer PE, Cook D, Jones G, Albert M, Elke G, Berger MM, Day AG: A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 2013, 368:1489?497. 107. Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M, Bontempo P, Pignalosa O, Vietri MT, Molinari AM, Sica V, Della CF, Napoli C: The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Anesth Analg 2004, 99:857?63. 108. Niki E: Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic Biol Med 2014, 66:2?2.doi:10.1186/s13054-014-0460-x Cite this article as: Oudemans-van Straaten et al.: Vitamin C revisited. Critical Care 2014 18:460.
Lameire et al. Critical Care (2016) 20:209 DOI 10.1186/s13054-016-1382-REVIEWOpen AccessAcute kidney injury in critically ill cancer patients: an updateNorbert Lameire1*, Raymond Vanholder1, Wim Van Biesen1 and Dominique BenoitAbstractPatients with cancer represent a growing group among actual ICU admissions (up to 20 ). Due to their increased susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment, these patients frequently develop acute kidney injury (AKI). A wide variety of definitions for AKI are still used in the cancer literature, despite existing guidelines on definitions and staging of AKI. Alternative diagnostic investigations such as Cystatin C and urinary biomarkers are discussed briefly. This review summarizes the literature between 2010 and 2015 on epidemiology and prognosis of AKI in this population. Overall, the causes of AKI in the setting of malignancy are similar to those in other clinical settings, including preexisting chronic kidney disease. In addition, nephrotoxicity induced by the anticancer treatments including the more recently introduced targeted therapies is increasingly observed. However, data are sometimes difficult to interpret because they are often presented from the oncological rather than from the nephrological point of view. Because the development of the acute tumor lysis syndrome is one of the major causes of AKI in patients with a high tumor burden or a high cell turnover, the diagnosis, risk factors, and preventive measures of the syndrome will be discussed. Finally, we will briefly discuss renal replacement therapy modalities and the emergence of chronic kidney disease in the growing subgroup of critically ill post-AKI survivors.Background The association between cancer and kidney disease has long been recognized but received extra attention after the creation of a `new’ nephrological subspecialty, called `onco-nephrology’.